Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy

Author(s): Liudmila V. Spirina*, Alexandra V. Avgustinovich, Sergey G. Afanas’ev, Olga V. Cheremisina, Maxim Yu. Volkov, Evgeny L. Choynzonov, Alexey K. Gorbunov, Evgeny A. Usynin

Journal Name: Current Drug Targets

Volume 21 , Issue 7 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Gastric cancer (GC) is biologically and genetically heterogeneous with complex carcinogenesis at the molecular level. Despite the application of multiple approaches in the GC treatment, its 5-year survival is poor. A major limitation of anti-cancer drugs application is intrinsic or acquired resistance, especially to chemotherapeutical agents. It is known that the effectiveness of chemotherapy remains debatable and varies according to the molecular type of GC. Chemotherapy has an established role in the management of GC. Perioperative chemotherapy or postoperative chemotherapy is applied for localized ones. Most of the advanced GC patients have a poor response to treatment and unfavorable outcomes with standard therapies.

Resistance substantially limits the depth and duration of clinical responses to targeted anticancer therapies. Through the use of complementary experimental approaches, investigators have revealed that cancer cells can achieve resistance through adaptation or selection driven by specific genetic, epigenetic, or microenvironmental alterations. Ultimately, these diverse alterations often lead to the activation of MAPK, AKT/mTOR, and Wnt/β-catenin signaling pathways that, when co-opted, enable cancer cells to survive drug treatments. We have summarized the mechanisms of resistance development to cisplatin, 5-fluorouracil, and multidrug resistance in the GC management. The complexity of molecular targets and components of signaling cascades altered in the resistance development results in the absence of significant benefits in GC treatment, and its efficacy remains low. The universal process responsible for the failure in the multimodal approach in GC treatment is autophagy. Its dual role in oncogenesis is the most unexplored issue. We have discussed the possible mechanism of autophagy regulation upon the action of endogenous factors and drugs. The experimental data obtained in the cultured GC cells need further verification. To overcome the cancer resistance and to prevent autophagy as the main reason of ineffective treatment, it is suggested the concept of the direct influence of autophagy molecular markers followed by the standard chemotherapy. Dozen of studies have focused on finding the rationale for the benefits of such complex therapy. The perspectives in the molecular-based management of GC are associated with the development of molecular markers predicting the protective autophagy initiation and search for novel targets of effective anticancer therapy.

Keywords: Molecular diagnosis and therapeutics, chemotherapy, tumor markers, autophagy, anticancer therapy, gastric cancer (GC).

[1]
Berretta S, Berretta M, Fiorica F, et al. Multimodal approach of advanced gastric cancer: based therapeutic algorithm. Eur Rev Med Pharmacol Sci 2016; 20(19): 4018-31.
[PMID: 27775797]
[2]
Pietrantonio F, De Braud F, Da Prat V, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 2013; 33(4): 1257-66.
[PMID: 23564763]
[3]
Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 2015; 19(1A): A68-77.
[http://dx.doi.org/10.5114/wo.2014.47136] [PMID: 25691825]
[4]
Stewart C, Chao J, Chen YJ, et al. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019; 4: 42.
[http://dx.doi.org/10.21037/tgh.2019.05.02] [PMID: 31231709]
[5]
Zhang H, Fan Q, Wei X. Chemotherapy sensitivity of gastric cancer. Clin Surg 2017; 2: 1400.
[PMID: 28255193]
[6]
Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol 2018; 24(26): 2818-32.
[http://dx.doi.org/10.3748/wjg.v24.i26.2818] [PMID: 30018477]
[7]
Wang S, Yuan L. Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine. Biosci Trends 2016; 10(3): 171-80.
[http://dx.doi.org/10.5582/bst.2016.01078] [PMID: 27251446]
[8]
Jiang GM, Tan Y, Wang H, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer 2019; 18(1): 17.
[http://dx.doi.org/10.1186/s12943-019-0944-z] [PMID: 30678689]
[9]
Spirina LV, Kondakova IV, Tarasenko NV, et al. Targeting of the akt/m-tor pathway: biomarkers of resistance to cancer therapy--
akt/m-tor pathway and resistance to cancer therapy. Zhongguo Fei Ai Za Zhi 2018; 21(1): 63-6.
[http://dx.doi.org/10.3779/j.issn.1009-3419.2018.01.09] [PMID: 29357975]
[10]
Marin JJ, Monte MJ, Blazquez AG, Macias RI, Serrano MA, Briz O. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacol Sin 2014; 35(1): 1-10.
[http://dx.doi.org/10.1038/aps.2013.131] [PMID: 24317012]
[11]
Jögi A, Vaapil M, Johansson M, Påhlman S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups J Med Sci 2012; 117(2): 217-24.
[http://dx.doi.org/10.3109/03009734.2012.659294] [PMID: 22376239]
[12]
Spirina LV, Usynin YA, Yurmazov ZA, Slonimskaya EM, Kolegova ES, Kondakova IV. Transcription factors NF-kB, HIF-1, HIF-2, growth factor VEGF, VEGFR2 and carboanhydrase IX mRNA and protein level in the development of kidney cancer metastasis Mol Biol (Mosk) 2017; 51(2): 372-7.
[http://dx.doi.org/10.7868/S0026898417020197] [PMID: 28537244]
[13]
Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010; 20(7): 697-706.
[http://dx.doi.org/10.1089/thy.2010.1646] [PMID: 20578891]
[14]
Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 2010; 29(1): 143-9.
[http://dx.doi.org/10.1007/s10555-010-9208-5] [PMID: 20111893]
[15]
Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 2017; 8(5): 8921-46.
[http://dx.doi.org/10.18632/oncotarget.13475] [PMID: 27888811]
[16]
García-Aranda M, Pérez-Ruiz E, Redondo M. Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. Int J Mol Sci 2018; 19(12)E3950
[http://dx.doi.org/10.3390/ijms19123950] [PMID: 30544835]
[17]
Du B, Shim JS. Targeting epithelial-mesenchymal transition (emt) to overcome drug resistance in cancer. Molecules 2016; 21(7)E965
[http://dx.doi.org/10.3390/molecules21070965] [PMID: 27455225]
[18]
Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012; 18(17): 2464-71.
[http://dx.doi.org/10.2174/13816128112092464] [PMID: 22372504]
[19]
Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T, Yousefi M. MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother 2015; 74: 191-9.
[http://dx.doi.org/10.1016/j.biopha.2015.08.009] [PMID: 26349984]
[20]
Wood KC. Mapping the pathways of resistance to targeted therapies. Cancer Res 2015; 75(20): 4247-51.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-1248] [PMID: 26392071]
[21]
Yang W, Ma J, Zhou W, et al. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. Expert Opin Ther Targets 2017; 21(11): 1063-75.
[http://dx.doi.org/10.1080/14728222.2017.1389900] [PMID: 28994330]
[22]
Wang P, Li Z, Liu H, Zhou D, Fu A, Zhang E. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun 2016; 479(1): 91-6.
[http://dx.doi.org/10.1016/j.bbrc.2016.09.040] [PMID: 27622325]
[23]
Huang H, Tang J, Zhang L, Bu Y, Zhang X. miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1. Int J Oncol 2018; 53(6): 2769-79.
[http://dx.doi.org/10.3892/ijo.2018.4593] [PMID: 30320370]
[24]
Zhang X, Bo P, Liu L, Zhang X, Li J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother 2017; 92: 580-5.
[http://dx.doi.org/10.1016/j.biopha.2017.04.111] [PMID: 28578256]
[25]
Wang SF, Chen MS, Chou YC, et al. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget 2016; 7(45): 74132-51.
[http://dx.doi.org/10.18632/oncotarget.12356] [PMID: 27708226]
[26]
Mo D, Fang H, Niu K, et al. Human helicase recql4 drives cisplatin resistance in gastric cancer by activating an akt-yb1-mdr1 signaling pathway. Cancer Res 2016; 76(10): 3057-66.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2361] [PMID: 27013200]
[27]
Wang L, Chunyan Q, Zhou Y, et al. BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients. Eur Rev Med Pharmacol Sci 2017; 21(18): 4064-70.
[PMID: 29028095]
[28]
Ye XL, Zhao YR, Weng GB, et al. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep 2015; 33(6): 2746-52.
[http://dx.doi.org/10.3892/or.2015.3898] [PMID: 25846650]
[29]
Lu C, Shan Z, Li C, Yang L. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother 2017; 86: 450-6.
[http://dx.doi.org/10.1016/j.biopha.2016.11.139] [PMID: 28012924]
[30]
Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res 2017; 36(1): 53.
[http://dx.doi.org/10.1186/s13046-017-0528-y] [PMID: 28407783]
[31]
Zhao J, Nie Y, Wang H, Lin Y. MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene 2016; 576(2 Pt 2): 828-33.
[http://dx.doi.org/10.1016/j.gene.2015.11.013] [PMID: 26589846]
[32]
Hu XF, Yao J, Gao SG, et al. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac J Cancer Prev 2013; 14(9): 5231-5.
[http://dx.doi.org/10.7314/APJCP.2013.14.9.5231] [PMID: 24175806]
[33]
Wang J, Hu W, Wang K, et al. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil. Int J Oncol 2016; 48(4): 1341-52.
[http://dx.doi.org/10.3892/ijo.2016.3371] [PMID: 26847910]
[34]
Ying LS, Yu JL, Lu XX, Ling ZQ. Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer. Dig Dis Sci 2013; 58(2): 414-22.
[http://dx.doi.org/10.1007/s10620-012-2381-3] [PMID: 23010741]
[35]
Jin J, Lv H, Wu J, et al. Regenerating Family Member 4 (Reg4) Enhances 5-Fluorouracil Resistance of Gastric Cancer Through Activating MAPK/Erk/Bim Signaling Pathway. Med Sci Monit 2017; 23: 3715-21.
[http://dx.doi.org/10.12659/MSM.903134] [PMID: 28759561]
[36]
Chen WY, Huang CY, Cheng WL, et al. Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil. Tumour Biol 2015; 36(12): 9537-44.
[http://dx.doi.org/10.1007/s13277-015-3668-8] [PMID: 26136123]
[37]
Yu B, Gu D, Zhang X, Liu B, Xie J. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer. J Genet Genomics 2017; 44(8): 375-83.
[http://dx.doi.org/10.1016/j.jgg.2017.04.008] [PMID: 28847472]
[38]
Han Y, Song C, Wang J, Tang H, Peng Z, Lu S. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol Carcinog 2018; 57(6): 722-34.
[http://dx.doi.org/10.1002/mc.22793] [PMID: 29436749]
[39]
Chen D, Jiao XL, Liu ZK, Zhang MS, Niu M. Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro. Eur Rev Med Pharmacol Sci 2013; 17(13): 1703-8.
[PMID: 23852891]
[40]
Kwon OH, Kim JH, Kim SY, Kim YS. TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation. Int J Oncol 2014; 44(2): 583-90.
[http://dx.doi.org/10.3892/ijo.2013.2211] [PMID: 24337061]
[41]
Kim HM, Kim SA, Park SB, Cho JH, Song SY. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth. Scand J Gastroenterol 2017; 52(5): 577-84.
[http://dx.doi.org/10.1080/00365521.2017.1278786] [PMID: 28110575]
[42]
He XX, Huang CK, Xie BS. Autophagy inhibition enhanced 5‑FU‑induced cell death in human gastric carcinoma BGC‑823 cells. Mol Med Rep 2018; 17(5): 6768-76.
[http://dx.doi.org/10.3892/mmr.2018.8661] [PMID: 29512733]
[43]
Huang D, Duan H, Huang H, et al. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep 2016; 6: 20502.
[http://dx.doi.org/10.1038/srep20502] [PMID: 26846307]
[44]
Huang R, Gu W, Sun B, Gao L. Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis. Mol Med Rep 2018; 17(5): 6387-96.
[http://dx.doi.org/10.3892/mmr.2018.8664] [PMID: 29512712]
[45]
Wu M, Guo L, Zuo Q. Correlation between cyclin-dependent kinase inhibitor p27kip1 and trastuzumab-resistance in gastric cancer Zhong Nan Da Xue Xue Bao Yi Xue Ban 2016; 41(5): 471-6.
[http://dx.doi.org/10.11817/j.issn.1672-7347.2016.05.004] [PMID: 27269920]
[46]
Ning L, Guo-Chun Z, Sheng-Li A, et al. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy. Tumour Biol 2016; 37(4): 5445-54.
[http://dx.doi.org/10.1007/s13277-015-4392-0] [PMID: 26563373]
[47]
Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22(2): 132-9.
[http://dx.doi.org/10.1016/j.ceb.2009.12.004] [PMID: 20056399]
[48]
Netea-Maier RT, Klück V, Plantinga TS, Smit JW. Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol (Lausanne) 2015; 6: 22.
[http://dx.doi.org/10.3389/fendo.2015.00022] [PMID: 25741318]
[49]
Eskelinen EL. Autophagy: Supporting cellular and organismal homeostasis by self-eating. Int J Biochem Cell Biol 2019; 111: 1-10.
[http://dx.doi.org/10.1016/j.biocel.2019.03.010] [PMID: 30940605]
[50]
Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008; 90(2): 313-23.
[http://dx.doi.org/10.1016/j.biochi.2007.08.014] [PMID: 17928127]
[51]
Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. Int J Mol Sci 2017; 18(9)E1865
[http://dx.doi.org/10.3390/ijms18091865] [PMID: 28846632]
[52]
Satoo K, Noda NN, Kumeta H, et al. The structure of Atg4B-LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. EMBO J 2009; 28(9): 1341-50.
[http://dx.doi.org/10.1038/emboj.2009.80] [PMID: 19322194]
[53]
Morell C, Bort A, Vara-Ciruelos D, et al. Up-regulated expression of lamp2 and autophagy activity during neuroendocrine differentiation of prostate cancer lncap cells. PLoS One 2016; 11(9)e0162977
[http://dx.doi.org/10.1371/journal.pone.0162977] [PMID: 27627761]
[54]
Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench 2015; 8(Suppl. 1): S6-S14.
[PMID: 26171139]
[55]
Cao Y, Luo Y, Zou J, et al. Autophagy and its role in gastric cancer. Clin Chim Acta 2019; 489: 10-20.
[http://dx.doi.org/10.1016/j.cca.2018.11.028] [PMID: 30472237]
[56]
Díaz P, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol 2018; 9: 5.
[http://dx.doi.org/10.3389/fmicb.2018.00005] [PMID: 29403459]
[57]
Qian HR, Yang Y. Functional role of autophagy in gastric cancer. Oncotarget 2016; 7(14): 17641-51.
[http://dx.doi.org/10.18632/oncotarget.7508] [PMID: 26910278]
[58]
Qin W, Li C, Zheng W, et al. Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget 2015; 6(37): 39839-54.
[http://dx.doi.org/10.18632/oncotarget.5674] [PMID: 26497999]
[59]
Lin X, Peng Z, Wang X, et al. Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death Dis 2019; 10(2): 139.
[http://dx.doi.org/10.1038/s41419-019-1314-x] [PMID: 30760701]
[60]
Spirina LV, Usynin EA, Yurmazov ZA, Slonimskaya EM, Kondakova IV. Effect of Targeted Therapy With Pazopanib on Expression Levels of Transcription, Growth Factors and Components of AKT/m-TOR Signaling Pathway in Patients with Renal Cell Carcinoma Asian Pac J Cancer Prev 2017; 18(11): 2977-83.
[61]
Li W, Zhou Y, Yang J, et al. Curcumin induces apoptosis and protective autophagy in human gastric cancer cells with different degree of differentiation Zhonghua Zhong Liu Za Zhi 2017; 39(7): 490-6.
[http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2017.07.003] [PMID: 28728293]
[62]
Fu H, Wang C, Yang D, et al. Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling. J Cell Physiol 2018; 233(6): 4634-42.
[http://dx.doi.org/10.1002/jcp.26190] [PMID: 28926094]
[63]
Kong P, Zhu X, Geng Q, et al. The microRNA-423-3p-bim axis promotes cancer progression and activates oncogenic autophagy in gastric cancer. Mol Ther 2017; 25(4): 1027-37.
[http://dx.doi.org/10.1016/j.ymthe.2017.01.013] [PMID: 28254439]
[64]
YiRen H, YingCong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017; 16(1): 174.
[http://dx.doi.org/10.1186/s12943-017-0743-3] [PMID: 29162158]
[65]
Li B, Wang W, Li Z, et al. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett 2017; 410: 212-27.
[http://dx.doi.org/10.1016/j.canlet.2017.09.035] [PMID: 28965855]
[66]
Sun Y, Jiang Y, Huang J, Chen H, Liao Y, Yang Z. CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway. Cancer Med 2017; 6(10): 2331-46.
[http://dx.doi.org/10.1002/cam4.1169] [PMID: 28857517]
[67]
Pei G, Luo M, Ni X, et al. Autophagy facilitates metadherin-induced chemotherapy resistance through the ampk/atg5 pathway in gastric cancer. Cell Physiol Biochem 2018; 46(2): 847-59.
[http://dx.doi.org/10.1159/000488742] [PMID: 29635244]
[68]
Zhou H, Yuan M, Yu Q, Zhou X, Min W, Gao D. Autophagy regulation and its role in gastric cancer and colorectal cancer. Cancer Biomark 2016; 17(1): 1-10.
[http://dx.doi.org/10.3233/CBM-160613] [PMID: 27314289]
[69]
Wang BJ, Zheng WL, Feng NN, et al. The effects of autophagy and pi3k/akt/m-tor signaling pathway on the cell-cycle arrest of rats primary sertoli cells induced by zearalenone. Toxins (Basel) 2018; 10(10): 398.
[http://dx.doi.org/10.3390/toxins10100398] [PMID: 30274213]
[70]
Wei WJ, Hardin H, Luo QY. Targeting autophagy in thyroid cancers. Endocr Relat Cancer 2019. pii: ERC-18-0502.R1. doi: 10.1530/ERC-18-0502
[http://dx.doi.org/10.1530/ERC-18-0502]
[71]
Yang M, Bai L, Yu W, et al. Expression of autophagy-associated proteins in papillary thyroid carcinoma. Oncol Lett 2017; 14(1): 411-5.
[http://dx.doi.org/10.3892/ol.2017.6101] [PMID: 28693184]
[72]
Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol 2013; 2013102735
[http://dx.doi.org/10.1155/2013/102735] [PMID: 23840208]
[73]
Towers CG, Thorburn A. Therapeutic targeting of autophagy. EBioMedicine 2016; 14: 15-23.
[http://dx.doi.org/10.1016/j.ebiom.2016.10.034] [PMID: 28029600]
[74]
Wei B, Huang Q, Huang S, Mai W, Zhong X. Trichosanthin-induced autophagy in gastric cancer cell MKN-45 is dependent on reactive oxygen species (ROS) and NF-κB/p53 pathway. J Pharmacol Sci 2016; 131(2): 77-83.
[http://dx.doi.org/10.1016/j.jphs.2016.03.001] [PMID: 27032906]
[75]
Li C, Wang Y, Wang C, Yi X, Li M, He X. Anticancer activities of harmine by inducing a pro-death autophagy and apoptosis in human gastric cancer cells. Phytomedicine 2017; 28: 10-8.
[http://dx.doi.org/10.1016/j.phymed.2017.02.008] [PMID: 28478808]
[76]
Chen PP, Ma XY, Lin Q, et al. Kangfuxin promotes apoptosis of gastric cancer cells through activating ER‑stress and autophagy. Mol Med Rep 2017; 16(6): 9043-50.
[http://dx.doi.org/10.3892/mmr.2017.7716] [PMID: 28990095]
[77]
Wei F, Jiang X, Gao HY, Gao SH. Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo. Int J Oncol 2017; 51(5): 1383-94.
[http://dx.doi.org/10.3892/ijo.2017.4134] [PMID: 29048624]
[78]
Valenzuela CA, Vargas L, Martinez V, Bravo S, Brown NE. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res 2017; 360(2): 390-6.
[http://dx.doi.org/10.1016/j.yexcr.2017.09.031] [PMID: 28947133]
[79]
Pasquier B. Autophagy inhibitors. Cell Mol Life Sci 2016; 73(5): 985-1001.
[http://dx.doi.org/10.1007/s00018-015-2104-y] [PMID: 26658914]
[80]
Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011; 147(1): 223-34.
[http://dx.doi.org/10.1016/j.cell.2011.08.037] [PMID: 21962518]
[81]
Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol 2014; 44(5): 1661-8.
[http://dx.doi.org/10.3892/ijo.2014.2313] [PMID: 24585095]
[82]
Byun S, Lee E, Lee KW. Therapeutic implications of autophagy inducers in immunological disorders, infection, and cancer. Int J Mol Sci 2017; 18(9): 1959.
[http://dx.doi.org/10.3390/ijms18091959] [PMID: 28895911]
[83]
Nagelkerke A, Sweep FC, Geurts-Moespot A, Bussink J, Span PN. Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagy. Semin Cancer Biol 2015; 31: 89-98.
[http://dx.doi.org/10.1016/j.semcancer.2014.05.004] [PMID: 24879905]
[84]
Hardie DG. AMPK and autophagy get connected. EMBO J 2011; 30(4): 634-5.
[http://dx.doi.org/10.1038/emboj.2011.12] [PMID: 21326174]
[85]
Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep 2015; 35(3)e00199
[http://dx.doi.org/10.1042/BSR20140141] [PMID: 26182361]
[86]
Wang H, Wang L, Cao L, et al. Inhibition of autophagy potentiates the anti-metastasis effect of phenethyl isothiocyanate through JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog 2018; 57(4): 522-35.
[http://dx.doi.org/10.1002/mc.22777] [PMID: 29278657]
[87]
Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013; 14(12): e535-47.
[http://dx.doi.org/10.1016/S1470-2045(13)70436-4] [PMID: 24176572]
[88]
Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016; 22(8): 2403-14.
[http://dx.doi.org/10.3748/wjg.v22.i8.2403] [PMID: 26937129]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 7
Year: 2020
Published on: 17 June, 2020
Page: [713 - 721]
Pages: 9
DOI: 10.2174/1389450120666191127113854
Price: $65

Article Metrics

PDF: 23
HTML: 5
PRC: 1